Intensity Therapeutics, Inc. (INTS) Stock Price & Analysis
Intensity Therapeutics, Inc. (INTS) fell 2.11% to USD 3.71 as of June 10, 2026 at 06:46 UTC, according to Nexqual real-time market data.
INTS last closed at USD 3.79; the session ranged USD 3.51–3.83 on volume of 39,945 shares. Market capitalization is $10.03M, with a 52-week range of USD 3.51–43.5 (NCM). Source: Nexqual, June 10, 2026 at 06:46 UTC.
Key Statistics (as of June 10, 2026 at 06:46 UTC)
| Price | USD 3.71 |
|---|---|
| Change | ▼ 2.11% (down) |
| Previous Close | USD 3.79 |
| Open | USD 3.78 |
| Day Range | USD 3.51 – 3.83 |
| 52-Week Range | USD 3.51 – 43.5 |
| Volume | 39,945 shares |
| Market Cap | $10.03M |
| Exchange | NCM |
Technical Analysis (INTS)
Nexqual's technical model rates INTS "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 14.1 (oversold) |
| vs SMA50 | Below (USD 5.01) |
| MACD | -0.35 (negative) |
Analyst Ratings (INTS)
Wall Street analysts rate INTS "None" based on 5 analysts, with a mean price target of USD 24.8 (range USD 12–32), per Nexqual as of June 10, 2026 at 06:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 24.8 |
| High Target | USD 32 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (INTS)
| EPS Estimate | USD -0.77 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.96 vs est -1.09 ▲ beat |
| 2025-09-30 | USD -1.5 vs est -1.5 ▲ beat |
| 2025-06-30 | USD -3.25 vs est -4.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:46 UTC.
Financials & Fundamentals (INTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -207.37% |
| Debt / Equity | 1.02 |
| Current Ratio | 4.86 |
| Total Cash | $10.24M |
| Total Debt | $102,000 |
| Free Cash Flow | $-5.27M |
Source: Nexqual, June 10, 2026 at 06:46 UTC.
Financial Health Score (INTS)
Nexqual rates Intensity Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -207%, ROA -90.4% |
Ownership (INTS)
| Insider Ownership | +4.55% |
|---|---|
| Institutional Ownership | +6.19% |
| Shares Outstanding | 2.70M |
| Float | 2.47M |
| Short % of Float | +2.92% |
Source: Nexqual, June 10, 2026 at 06:46 UTC.
Leadership (INTS)
Intensity Therapeutics, Inc. is led by Lewis H. Bender M.A., M.B.A., M.S. (age 66), Founder, President, CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 06:46 UTC.
| Founder, President, CEO & Chairman of the Board | Lewis H. Bender M.A., M.B.A., M.S. (age 66) |
|---|---|
| Chief Financial Officer | Joseph Talamo (age 56) |
| Executive Vice President of Corporate Finance | James M. Ahlers (age 61) |
Major Backers & Investors (INTS)
Notable institutional backers of Intensity Therapeutics, Inc. include Sapient Capital LLC, Nano Cap New Millennium Growth Fund L P, Rothschild Wealth, LLC, according to Nexqual as of June 10, 2026 at 06:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sapient Capital LLC | 0.96% |
| Nano Cap New Millennium Growth Fund L P | 0.92% |
| Rothschild Wealth, LLC | 0.86% |
| Fidelity | 0.78% |
| Mesirow Financial Investment Management, Inc. | 0.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.58% |
| Geode Capital | 0.96% |
Source: Nexqual, June 10, 2026 at 06:46 UTC.
From Intensity Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- If we successfully execute the agreed-upon plan, we expect that the CMC portion of a New Drug Application ("NDA") should be acceptable to the FDA for product approval and registration (subject to final NDA review).
- Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules.
- Our Proprietary Drug Discovery platform, DfuseRx SM Since our inception, we have conducted research using our discovery platform.
- Our technology platform allows us to identify novel product formulations and test the products' activity in animal or test tube models of cancer.
Partnerships
- In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.
- In 2020, as part of our IT-01 Study, we entered into an agreement with BMS to evaluate the safety and efficacy of INT230-6 with Yervoy ® (ipilimumab), BMS's CTLA-4 immune checkpoint inhibitor, in patients with breast (17%), liver (5%), and advanced sarcoma cancer (78%).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MSAI | MultiSensor AI Holdings, Inc. | USD 4.93 | ▲ 4.67% |
| FEMY | Femasys Inc. | USD 5.25 | ▼ 14.22% |
| AIRE | reAlpha Tech Corp. | USD 2.02 | ▼ 3.81% |
| PCSA | Processa Pharmaceuticals, Inc. | USD 2.04 | ▼ 19.25% |
| IXHL | Incannex Healthcare Inc. | USD 3.67 | ▲ 25.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:46 UTC. This page is informational and not investment advice.